Brainshake closes €3.5M to advance regulatory approval of blood analysis service
Finnish Brainshake has raised 3.5 million euros in Series A funding. The investment will be used to advance regulatory approval and internationalization of its blood analysis service.
Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods. Biomarkers reflect the health state of an individual and can be used to predict disease risk in chronic diseases. Brainshake’s blood analysis, backed up by 100 peer-reviewed scientific publications, is used by leading universities globally.
“Our technology has been proven by peer-reviewed science and the epidemiological studies show the power of our data in risk assessment of chronic diseases. Now we are bringing the technology to routine healthcare with the ultimate target to enable prevention of the world’s number one health problem”, says Teemu Suna, CEO, Brainshake.
The 3.5 million investment is led by Cor Group, a Finnish growth venture, joining Brainshake as a shareholder and long-term strategic partner. Other parties of the financial package include Tekes, Nordea and Finnvera. Brainshake is also a member of one of the world’s biggest health-focused start-up accelerators StartUp Health.
“We have worked in the global healthcare market for nearly 30 years, and consider Brainshake’s blood analysis highly impressive. We look forward to working together to create a global market leader and to advance the company’s mission to transform preventive medicine in chronic diseases together with our Group. Our goal is to work with Brainshake as a long-term strategic partner, an active member of the board and co-owner”, says Olli Karhi, board member, Cor Group.
Helsinki-based Brainshake has 15 employees in Finland. In 2015, the company’s turnover was 1,6 million euros.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Epigenomics AG Receives Allowances for Key Patents in Europe - Patents cover biomarker mPITX2 for prostate and breast cancer indications
Measuring chemistry: local fingerprint of hydrogen bonding captured in experiments
Analytik Jena aquires majority of distributor in Romania - Analytik Jena took over 70% of the company shares of a Romanian company based on a cash-share deal.
Nature-inspired coatings could power tiny chemistry labs for medical testing and more - Researchers develop polymer coating that enables low surface tension liquids to be transported over distances 15 times longer than currently possible, without losing any of the liquid
BOSELLO now fully part of the ZEISS Group - BOSELLO HIGH TECHNOLOGY becomes Carl Zeiss X-ray Technologies Srl
Destination China as Level Sensors and Transmitters Markets Make a Comeback - Increased investments in manufacturing and greater automated production to fuel demand in emerging economies
New study supports use of PCA3-based test for prostate cancer diagnosis - European commercialization in progress
European multi-center study suggests PCA3 test more accurate for prostate cancer
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture
Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity
Chiral Technologies Europe Acquires ChromTech Ltd. of U.K.
